Ocuphire Pharma Investor Updates

P 23 Summary of Positive VEGA-1 Phase 2 Results for Nyxol Eye Drops Efficacy Data In Subjects With A Favorable Safety Profile In Presbyopia With Nyxol And Low Dose Pilocarpine • Met the primary endpoint with statistical significance for binocular photopic near vision at 1 hour 61% Nyxol + LDP gained 15 letters (3 lines) or more vs. 28% Placebo (33% Placebo Adjusted) • Met the Phase 3 co-primary endpoint vs. placebo gaining 15 letters (3 lines) near vision with less than 5 letters of distance vision loss ● ● Met many key secondary endpoints Rapid onset at 30 min - - - - Durable near vision improvement through at least 6 hours Nyxol+LDP was numerically better than each component through 2-hours Sustained significant reduction in PD over at least 18 hours due the durability effects of Nyxol Near vision efficacy seen monocularly and binocularly Also, efficacy data in both light and dark iris colors Favorable safety profile for Nyxol + LDP No serious AEs No systemic AEs were observed in >5% subjects No headaches, no browaches, and no blurry vision AEs were reported Only mild, transient conjunctival hyperemia observed in <5% of subjects Positive Phase 2 results lead to advancing Phase 3 presbyopia program - VEGA-1 Topline Reports (TLR) Ocuphire PHARMA

View entire presentation